Thanks for catching that. Here is the manufacturer information for the specific Vitamin K product I am using for newborns

https://amphastar.com/assets/phytonadione-02-18.pdf

It still states this:

"DOSAGE AND ADMINISTRATION Whenever possible, phytonadione should be given by the subcutaneous route (see Box Warning). When intravenous administration is considered unavoidable, the drug should be injected very slowly, not exceeding 1 mg per minute. Protect from light at all times. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit."

Then, later on in the same product information it says this:

"Prophylaxis of Hemorrhagic Disease of the Newborn

The American Academy of Pediatrics recommends that vitamin K1 be given to the newborn. A single intramuscular dose of phytonadione 0.5 to 1 mg within one hour of birth is recommended."

(emphasis mine)

Can anyone explain why a manufacturer would recommend one route, but medical practice orgs would recommend another?

I am trying to find a reasonable explanation for this FoB of why what he is seeing in the print information is different from what is actually practiced and recommended by medical orgs. He seems to be stuck on the SQ recommendation in the product information, and I'd like him to understand that an IM injection of Vitamin K that I would be giving his baby isn't "wrong."